AAI Acquires CAC - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

AAI Acquires CAC


ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

Wilmington, NC (Oct. 26)—AAIPharma Inc. (www.aaipharma.com) completed its acquisition of contract research organization Cvitkovic & Associes Consultants S.A. (CAC, Le Kremlin Bicetre, France). CAC, which specializes in oncology drug development and medical consulting, will form the foundation of AAIOncology, a global business unit dedicated to developing cancer-fighting drugs.

According to Vito Mangiardi, AAI’s president of North American operations, “The experience and expertise brought by our new colleagues in the area of … oncology will significantly strengthen our company’s ability to execute large and global late-stage clinical development programs.”

The acquisition was made possible through a rights offering to existing shareholders and option holders that raised $30 million. The offering was backstopped by a group of principal shareholders led by JPMorgan.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here